Statin therapy is associated with improved survival in incident peritoneal dialysis patients: Propensity-matched comparison

Nephrology Dialysis Transplantation

Volumn 26, Issue 12, 2011, Pages 4090-4094

  Lee, Jung Eun ^a   Oh, Kook Hwan ^b   Choi, Kyu Hun ^c   Kim, Soon Bae ^d   Kim, Yong Soo ^e   Do, Jun Young ^f   Kim, Yong Lim ^g   Kim, Dae Joong ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d University of Ulsan   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f Young Nam University Hospital   (South Korea)

^g Kyungpook National University School of Medicine   (South Korea)

Author keywords

end stage renal disease; mortality; peritoneal dialysis; statin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; FEMALE; HAZARD RATIO; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; PERITONEAL DIALYSIS; PRESCRIPTION; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK REDUCTION; SEX RATIO; SURVIVAL RATE;

COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 82255181441     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr229     Document Type: Article

References (21)

1. Lindner A, Charra B, Sherrard DJ et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119 (Pubitemid 28527268)
3. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169 (Pubitemid 37337595)
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389
5. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307
6. Seliger SL, Weiss NS, Gillen DL et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; 61: 297-304 (Pubitemid 34075157)
7. Mason NA, Bailie GR, Satayathum S et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 2005; 45: 119-126 (Pubitemid 40038052)
8. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41:I-IV S1-S91
9. Wanner C, Krane V, MarzWet al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248 (Pubitemid 41058323)
10. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407
11. Johnson DW, Dent H, Hawley CM et al. Association of dialysis modality and cardiovascular mortality in incident dialysis patients. Clin J Am Soc Nephrol 2009; 4: 1620-1628
12. Beddhu S, Bruns FJ, SaulMet al. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med 2000; 108: 609-613 (Pubitemid 30336599)
13. Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169-183
14. Kronenberg F, Konig P, Neyer U et al. Multicenter study of lipoprotein( a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6: 110-120
15. Lam NN, Jain AK, Hackam DG et al. Results of a randomized controlled trial on statin use in dialysis patients had no influence on statin prescription. Kidney Int 2009; 76: 1172-1179
16. Karumanchi SA, Thadhani R. Kidney complications: why don't statins always work? Nat Med 2010; 16: 38-40
17. SHARP Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering lowdensity lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010; 160: 785-794
18. Navaneethan SD, Hegbrant J, Strippoli GF. Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 2011; 20: 146-152
19. Weinhandl ED, Foley RN, Gilbertson DT et al. Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients. J Am Soc Nephrol 2010; 21: 499-506
20. Han SH, Ahn SV, Yun JY et al. Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions. Am J Kidney Dis 2009; 54: 711-720
21. Sipahioglu MH, Aybal A, Unal A et al. Patient and technique survival and factors affecting mortality on peritoneal dialysis in Turkey: 12 years' experience in a single center. Perit Dial Int 2008; 28: 238-245 (Pubitemid 352003037)